De Costa BR[au] - Search Results

Year	Number of Results
1988	2
1989	10
1990	19
1991	17
1992	13
1993	19
1994	12
1995	5
1996	4
1997	1
1998	2
1999	2
2000	2
2001	2
2022	0

1

Drug specificity of pharmacological dystonia.

Matsumoto RR, Hemstreet MK, Lai NL, Thurkauf A, De Costa BR, Rice KC, Hellewell SB, Bowen WD, Walker JM. Matsumoto RR, et al. Among authors: de costa br. Pharmacol Biochem Behav. 1990 May;36(1):151-5. doi: 10.1016/0091-3057(90)90141-4. Pharmacol Biochem Behav. 1990. PMID: 2161543

2

Cannabinoid receptor localization in brain.

Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC. Herkenham M, et al. Among authors: de costa br. Proc Natl Acad Sci U S A. 1990 Mar;87(5):1932-6. doi: 10.1073/pnas.87.5.1932. Proc Natl Acad Sci U S A. 1990. PMID: 2308954 Free PMC article.

3

The in vitro pharmacological characterization of naloxone benzoylhydrazone.

Berzetei-Gurske IP, White A, Polgar W, DeCosta BR, Pasternak GW, Toll L. Berzetei-Gurske IP, et al. Eur J Pharmacol. 1995 Apr 24;277(2-3):257-63. doi: 10.1016/0014-2999(95)00088-3. Eur J Pharmacol. 1995. PMID: 7493617

4

Kappa opioid effects on fetal behavior: central administration of U50,488.

Petrov ES, Varlinskaya EI, Robinson SR, Smotherman WP, de Costa BR, Rice KC. Petrov ES, et al. Among authors: de costa br. Physiol Behav. 1994 Jul;56(1):175-82. doi: 10.1016/0031-9384(94)90276-3. Physiol Behav. 1994. PMID: 8084898

5

Pharmacological activities of optically pure enantiomers of the kappa opioid agonist, U50,488, and its cis diastereomer: evidence for three kappa receptor subtypes.

Rothman RB, France CP, Bykov V, De Costa BR, Jacobson AE, Woods JH, Rice KC. Rothman RB, et al. Among authors: de costa br. Eur J Pharmacol. 1989 Aug 29;167(3):345-53. doi: 10.1016/0014-2999(89)90443-3. Eur J Pharmacol. 1989. PMID: 2553442 Free article.

6

Corticotropin-releasing hormone augments natural killer cell activity through a naloxone-sensitive pathway.

Carr DJ, DeCosta BR, Jacobson AE, Rice KC, Blalock JE. Carr DJ, et al. J Neuroimmunol. 1990 Jun;28(1):53-61. doi: 10.1016/0165-5728(90)90040-t. J Neuroimmunol. 1990. PMID: 2160475

7

Two novel sigma receptor ligands, BD1047 and LR172, attenuate cocaine-induced toxicity and locomotor activity.

McCracken KA, Bowen WD, de Costa BR, Matsumoto RR. McCracken KA, et al. Among authors: de costa br. Eur J Pharmacol. 1999 Apr 16;370(3):225-32. doi: 10.1016/s0014-2999(99)00113-2. Eur J Pharmacol. 1999. PMID: 10334496

8

Dissociation of the motor effects of (+)-pentazocine from binding to sigma 1 sites.

Matsumoto RR, Bowen WD, Walker JM, Patrick SL, Zambon AC, Vo VN, Truong DD, De Costa BR, Rice KC. Matsumoto RR, et al. Among authors: de costa br. Eur J Pharmacol. 1996 Apr 22;301(1-3):31-40. doi: 10.1016/0014-2999(96)00008-8. Eur J Pharmacol. 1996. PMID: 8773444

9

Neuronal localization of cannabinoid receptors in the basal ganglia of the rat.

Herkenham M, Lynn AB, de Costa BR, Richfield EK. Herkenham M, et al. Among authors: de costa br. Brain Res. 1991 May 3;547(2):267-74. doi: 10.1016/0006-8993(91)90970-7. Brain Res. 1991. PMID: 1909204

10

GBR12909 attenuates cocaine-induced activation of mesolimbic dopamine neurons in the rat.

Baumann MH, Char GU, De Costa BR, Rice KC, Rothman RB. Baumann MH, et al. Among authors: de costa br. J Pharmacol Exp Ther. 1994 Dec;271(3):1216-22. J Pharmacol Exp Ther. 1994. PMID: 7996429

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results